BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tang H, Griffin J, Innaimo S, Lehman-Mckeeman L, Llamoso C. The Discovery and Development of a Potent Antiviral Drug, Entecavir, for the Treatment of Chronic Hepatitis B. J Clin Transl Hepatol 2013;1:51-8. [PMID: 26357607 DOI: 10.14218/JCTH.2013.00006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
Number Citing Articles
1 Stasi C, Silvestri C, Voller F. Hepatitis B vaccination and immunotherapies: an update. Clin Exp Vaccine Res. 2020;9:1-7. [PMID: 32095435 DOI: 10.7774/cevr.2020.9.1.1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
2 Seley-Radtke KL, Yates MK. The evolution of nucleoside analogue antivirals: A review for chemists and non-chemists. Part 1: Early structural modifications to the nucleoside scaffold. Antiviral Res 2018;154:66-86. [PMID: 29649496 DOI: 10.1016/j.antiviral.2018.04.004] [Cited by in Crossref: 146] [Cited by in F6Publishing: 108] [Article Influence: 36.5] [Reference Citation Analysis]
3 Yuan G, Hu C, Zhou Y, Liu J, Huang H, Li Y, Yang D, Zhou F, Zhang YY, Zhou Y. A different inhibitor is required for overcoming entecavir resistance: a comparison of four rescue therapies in a retrospective study. Br J Clin Pharmacol 2017;83:2259-65. [PMID: 28511283 DOI: 10.1111/bcp.13330] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]